Editas Medicine (EDIT) plans to raise $100 million in an IPO on Wednesday, February 3rd. The company will issue 5,900,000 shares at a price of $16.00-$18.00 per share.

The company has a market-cap of $606.9 million.

Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine provided the following description of their company for its IPO: “We are a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. We believe that we have entered a new era of genomic medicine as the growth of genomic information in recent decades has significantly expanded the understanding of genetically defined diseases. A new technology known as CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR associated protein 9) has the potential to achieve precise, directed changes in DNA. “.

Editas Medicine was founded in 2013 and has 55 employees. The company is located at 300 Third Street, First Floor, Cambridge, MA 02142, US and can be reached via phone at (617) 401-9000 or on the web at http://www.editasmedicine.com.

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.